PMID- 19523167
OWN - NLM
STAT- MEDLINE
DCOM- 20091221
LR  - 20181201
IS  - 1365-2826 (Electronic)
IS  - 0953-8194 (Linking)
VI  - 21
IP  - 9
DP  - 2009 Sep
TI  - Central adiponectin functions to inhibit arginine vasopressin release in 
      conscious rats.
PG  - 753-9
LID - 10.1111/j.1365-2826.2009.01894.x [doi]
AB  - The adipocyte-derived hormone adiponectin plays an important role in modulating 
      energy homeostasis through peripheral tissues and the central nervous system. 
      Several studies have reported that adiponectin exists in cerebrospinal fluid and 
      that adiponectin receptors are expressed in the hypothalamus, including the 
      paraventricular nucleus (PVN), which plays a key role in controlling pituitary 
      hormone secretion. Furthermore, it has been reported that magnocellular arginine 
      vasopressin (AVP) neurones within the PVN express adiponectin receptors. These 
      findings suggest a central role of adiponectin in the modulation of 
      neuroendocrinological functions. In the present study, we investigated the effect 
      of centrally-administered adiponectin on AVP release in conscious rats. 
      Intracerebroventricular (i.c.v.) administration of adiponectin significantly 
      reduced the basal plasma AVP concentration in a dose-dependent manner, with a 
      maximal effect being obtained 10 min after administration. The plasma AVP 
      increase in response to either hyperosmolar or hypovolaemic stimulation was also 
      significantly attenuated by an i.c.v. injection of adiponectin. Treatment with 
      AMP-activated protein kinase (AMPK) inhibitor compound C (100 nmol, i.c.v.) 
      partially reversed the inhibitory effects of adiponectin on AVP release. These 
      findings suggest that central adiponectin plays an inhibitory role in the 
      osmoregulation and baroregulation of AVP release, that the AMPK pathway is at 
      least partly involved in the action of adiponectin, and further suggest a novel 
      physiological or pathophysiological role for central adiponectin in water balance 
      via inhibition of AVP release.
FAU - Iwama, Shintaro
AU  - Iwama S
AD  - Department of Endocrinology and Diabetes, Nagoya University Graduate School of 
      Medicine, Japan.
FAU - Sugimura, Yoshihisa
AU  - Sugimura Y
FAU - Murase, Takashi
AU  - Murase T
FAU - Hiroi, Maiko
AU  - Hiroi M
FAU - Goto, Motomitsu
AU  - Goto M
FAU - Hayashi, Masayuki
AU  - Hayashi M
FAU - Arima, Hiroshi
AU  - Arima H
FAU - Oiso, Yutaka
AU  - Oiso Y
LA  - eng
PT  - Journal Article
DEP - 20090612
PL  - United States
TA  - J Neuroendocrinol
JT  - Journal of neuroendocrinology
JID - 8913461
RN  - 0 (Adiponectin)
RN  - 0 (Narcotic Antagonists)
RN  - 0 (Receptors, Opioid, kappa)
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 36OOQ86QM1 (norbinaltorphimine)
RN  - 5S6W795CQM (Naltrexone)
SB  - IM
MH  - Adiponectin/administration & dosage/chemistry/*pharmacology/*physiology
MH  - Animals
MH  - Arginine Vasopressin/*metabolism
MH  - Blood Pressure/drug effects
MH  - Consciousness/physiology
MH  - Dose-Response Relationship, Drug
MH  - Down-Regulation/drug effects
MH  - Heart Rate/drug effects
MH  - Hypovolemia/chemically induced/metabolism/physiopathology
MH  - Injections, Intraventricular
MH  - Male
MH  - Naltrexone/analogs & derivatives/pharmacology
MH  - Narcotic Antagonists/pharmacology
MH  - Osmolar Concentration
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Opioid, kappa/antagonists & inhibitors
MH  - Time Factors
MH  - Water-Electrolyte Balance/drug effects
EDAT- 2009/06/16 09:00
MHDA- 2009/12/22 06:00
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2009/12/22 06:00 [medline]
AID - JNE1894 [pii]
AID - 10.1111/j.1365-2826.2009.01894.x [doi]
PST - ppublish
SO  - J Neuroendocrinol. 2009 Sep;21(9):753-9. doi: 10.1111/j.1365-2826.2009.01894.x. 
      Epub 2009 Jun 12.